AlphAIalphai — Financial news for AI agents
finance.yahoo.comJUL 304 min read$GKOS

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

Original reporting
finance.yahoo.com
Published Jul 30, 2026, 4:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Glaukos Q2 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GKOSNeutralMed
01

Why it matters

Management reiterated full-year gross margin targets and provided specific drivers for mix (iDose TR and Epioxa). The key incremental trading risk is Q3 volatility tied to Epioxa’s shift from Photrexa and a miscellaneous billing code to a permanent product-specific J-code effective July 1.

02

Market read

Traders get actionable guidance-level details: gross margin target maintained, operating expense outlook provided, and a near-term reimbursement/billing transition flagged as a likely source of Q3 volatility.

03

What to watch

International FX tailwinds are expected to diminish in 2H, so investors may need to separate currency effects from underlying growth when modeling full-year international revenue.

Relevance 7/10Novelty 6/10Timing: ahead of Q3 results, with transition issues expected to show up in Q3 and ease in Q4

Background

The piece summarizes Glaukos’ Q2 earnings call, focusing on iDose TR performance, Medicare LCD activity, international glaucoma and corneal franchise trends, and pipeline/profitability updates.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Glaukos guided 2026 gross margin to 84% to 86% and flagged Q3 volatility from Epioxa J-code transition effective July 1.

Expected impact

Choppy trading risk into and through Q3 as investors weigh transition-related reimbursement friction versus improving gross margin and international growth outlook.

Evidence & confidence

The article provides specific management targets (gross margin range, operating expense outlook) and a concrete operational catalyst (J-code transition July 1) that can affect near-term demand capture and billing behavior.

Market effects

Sector

Could influence sentiment toward ophthalmic medtech reimbursement dynamics and MIGS/corneal franchise durability.

Regional

International growth outlook is maintained but Germany and Switzerland face reimbursement and competitive trialing headwinds.

Global

CMS proposed 2027 rules and LCD proposals for iDose TR may affect broader US reimbursement expectations for glaucoma therapies.

Counterpoint

What could challenge this read

If the Epioxa J-code transition issues resolve faster than management expects, the market may over-discount Q3 volatility and re-rate the franchise.

Key entities

  • company
    Glaukos

    NYSE-listed medical technology company focused on glaucoma and corneal therapies, including iDose TR and Epioxa.

  • regulator
    CMS

    US Centers for Medicare and Medicaid Services, referenced for proposed 2027 rules affecting reimbursement for Glaukos procedures.

  • product
    Epioxa

    FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, with a permanent J-code effective July 1.

Read at source← All news

Related articles

AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 20
$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min